Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 243 Stomach Neoplasms 23 Breast Neoplasms, Male 16 Neoplasm Metastasis 14 Neoplasms 8 Inflammatory Breast Neoplasms 8 Esophageal Neoplasms 8 Brain Neoplasms 8 Colorectal Neoplasms 6 Adenocarcinoma Of Esophagus 4 Urologic Neoplasms 3 Triple Negative Breast Neoplasms 3 HER2-positive Breast Cancer 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma, Ductal, Breast 3 Gallbladder Neoplasms 2 Endometrial Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Lobular 2 Carcinoma, Intraductal, Noninfiltrating 2 Biliary Tract Neoplasms 2 Adenocarcinoma 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Solid Cancers 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Patient Preference 1 Patient Compliance 1

Interventions

Lapatinib 2 ribociclib 1 Trastuzumab 1 Paclitaxel 1 Letrozole 1 Goserelin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Osteitis Deformans × Trastuzumab × Clear all

NCT00553358 2021-09-21

Neo ALTTO

Novartis

Phase 3 Completed

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

Data powered by HemOnc (CC BY 4.0) Colophon ⚡